Prescribing Benzodiazepines and Stimulants in OUD Treatment: The Risks and the Benefits
Outline and Key Points covered by this training includes:
- Prescribing benzodiazepines to people with opioid use disorder
- The most effective ADHD treatment for OUD
- Review the spectrum of attitudes towards prescribing benzodiazepines and risk-benefit ratio
Target Audience
This course is designed for health care professionals including physicians, nurses, patients and caregivers, among others.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Review the risks and benefits of prescribing benzodiazepines for patients receiving OUD treatment
- Implement benzodiazepine prescribing practices that minimize harm
- Review the risks and benefits of prescribing stimulants for patients receiving OUD treatment
- Implement stimulant prescribing practices that minimize harm
Disclaimer Statement:
The information presented at this activity represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the UPMC Center for Continuing Education in the Health Sciences, UPMC / University of Pittsburgh Medical Center or Affiliates and University of Pittsburgh School of Medicine. Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each program attendee must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
Course Director:
- Tae Woo (Ted) Park, MD - Assistant Professor of Psychiatry, Department of Psychiatry, University of Pittsburgh
Conflict of Interest Disclosure:
No planners, members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose.
In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME) and the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician (CME)
The University of Pittsburgh designates this enduring material activity for a maximum of 0.75 AMA PRA Category 1 Credit[s]™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.
DEA Medication Access and Training Expansion (MATE) Act
This training is designed to meet the training requirements for the Medication Access and Training Expansion (MATE) Act of 2023.
Pennsylvania Opioid/Pain Management Credit (physicians only)
This activity has been designated as and qualifies for Opioid/Pain Management Credit. It is the responsibility of the learner to maintain the educational presentation or conference agenda as evidence, if needed for audit purpose
Available Credit
- 0.75 AMA PRA Category 1 Credit™The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
- 0.75 Opioid Education
- 0.75 Attendance
- 0.75 Opioid Education
Choose Register/Complete Course to complete the module.
First time Users: If you have never completed training on this website, please select register in the upper right hand corner of the webpage.
Returning Users: If you have completed training on this website, please log in in the upper right hand corner of the webpage.